Brokerages expect Insulet Co. (NASDAQ:PODD) to announce earnings per share (EPS) of ($0.19) for the current fiscal quarter, according to Zacks. Nine analysts have provided estimates for Insulet’s earnings, with the lowest EPS estimate coming in at ($0.26) and the highest estimate coming in at ($0.08). Insulet reported earnings per share of ($0.17) in the same quarter last year, which suggests a negative year over year growth rate of 11.8%. The business is expected to announce its next earnings report after the market closes on Thursday, May 3rd.

On average, analysts expect that Insulet will report full-year earnings of ($0.29) per share for the current fiscal year, with EPS estimates ranging from ($0.40) to ($0.14). For the next fiscal year, analysts expect that the firm will post earnings of $0.32 per share, with EPS estimates ranging from $0.04 to $0.71. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Insulet.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.04). Insulet had a negative net margin of 5.79% and a negative return on equity of 29.73%. The business had revenue of $130.50 million during the quarter, compared to analyst estimates of $125.16 million. During the same period in the previous year, the business posted ($0.16) EPS. The business’s revenue for the quarter was up 26.0% compared to the same quarter last year.

PODD has been the subject of several research reports. UBS raised shares of Insulet from a “market perform” rating to an “outperform” rating in a research report on Monday, January 8th. Raymond James raised shares of Insulet from a “market perform” rating to an “outperform” rating and set a $80.00 price target for the company in a research report on Monday, January 8th. Zacks Investment Research cut Insulet from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. BidaskClub upgraded Insulet from a “sell” rating to a “hold” rating in a research note on Friday, January 26th. Finally, Barclays restated an “overweight” rating and set a $90.00 price objective (up from $85.00) on shares of Insulet in a research note on Thursday, February 22nd. Seven analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $76.32.

In other news, EVP Bradley A. Thomas sold 3,500 shares of Insulet stock in a transaction on Friday, March 16th. The stock was sold at an average price of $85.00, for a total transaction of $297,500.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director John A. Fallon sold 9,000 shares of Insulet stock in a transaction on Wednesday, March 14th. The stock was sold at an average price of $84.10, for a total value of $756,900.00. The disclosure for this sale can be found here. Insiders have sold a total of 28,800 shares of company stock worth $2,412,739 over the last quarter. Company insiders own 3.60% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Virtus Fund Advisers LLC raised its stake in Insulet by 30.0% in the 4th quarter. Virtus Fund Advisers LLC now owns 4,244 shares of the medical instruments supplier’s stock valued at $293,000 after acquiring an additional 980 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Insulet by 42.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,283 shares of the medical instruments supplier’s stock valued at $227,000 after acquiring an additional 981 shares during the period. Russell Investments Group Ltd. raised its stake in Insulet by 3.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 30,200 shares of the medical instruments supplier’s stock valued at $1,662,000 after acquiring an additional 1,146 shares during the period. First Mercantile Trust Co. raised its stake in Insulet by 8.4% in the 4th quarter. First Mercantile Trust Co. now owns 14,840 shares of the medical instruments supplier’s stock valued at $1,024,000 after acquiring an additional 1,150 shares during the period. Finally, Strs Ohio raised its stake in Insulet by 17.1% in the 4th quarter. Strs Ohio now owns 8,200 shares of the medical instruments supplier’s stock valued at $565,000 after acquiring an additional 1,200 shares during the period.

NASDAQ PODD opened at $86.69 on Friday. Insulet has a 12-month low of $38.43 and a 12-month high of $89.63. The company has a debt-to-equity ratio of 3.57, a current ratio of 6.24 and a quick ratio of 5.85. The firm has a market capitalization of $5,201.81, a P/E ratio of -188.46 and a beta of 1.38.

ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Expect Insulet Co. (PODD) to Post -$0.19 EPS” was first posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2018/04/20/zacks-analysts-expect-insulet-co-podd-to-post-0-19-eps.html.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.